Literature DB >> 29739874

PTEN Regulates Nonhomologous End Joining By Epigenetic Induction of NHEJ1/XLF.

Parker L Sulkowski1, Susan E Scanlon2, Sebastian Oeck3,4, Peter M Glazer5,3.   

Abstract

DNA double-strand breaks (DSB) are the most cytotoxic DNA lesions, and up to 90% of DSBs require repair by nonhomologous end joining (NHEJ). Functional and genomic analyses of patient-derived melanomas revealed that PTEN loss is associated with NHEJ deficiency. In PTEN-null melanomas, PTEN complementation rescued the NHEJ defect; conversely, suppression of PTEN compromised NHEJ. Mechanistic studies revealed that PTEN promotes NHEJ through direct induction of expression of XRCC4-like factor (NHEJ1/XLF), which functions in DNA end bridging and ligation. PTEN was found to occupy the NHEJ1 gene promoter and to recruit the histone acetyltransferases, PCAF and CBP, inducing XLF expression. This recruitment activity was found to be independent of its phosphatase activity, but dependent on K128, a site of regulatory acetylation on PTEN. These findings define a novel function for PTEN in regulating NHEJ DSB repair, and therefore may assist in the design of individualized strategies for cancer therapy.Implications: PTEN is the second most frequently lost tumor suppressor gene. Here it is demonstrated that PTEN has a direct and novel regulatory role in NHEJ, a key DNA repair pathway in response to radiation and chemotherapy. Mol Cancer Res; 16(8); 1241-54. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29739874      PMCID: PMC6072556          DOI: 10.1158/1541-7786.MCR-17-0581

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  53 in total

1.  XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining.

Authors:  Peter Ahnesorg; Philippa Smith; Stephen P Jackson
Journal:  Cell       Date:  2006-01-27       Impact factor: 41.582

2.  Chromatin PTEN is involved in DNA damage response partly through regulating Rad52 sumoylation.

Authors:  Byeong Hyeok Choi; Yan Chen; Wei Dai
Journal:  Cell Cycle       Date:  2013-09-18       Impact factor: 4.534

3.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

4.  Transcriptional activation of human matrix metalloproteinase-9 gene expression by multiple co-activators.

Authors:  Xueyan Zhao; Etty N Benveniste
Journal:  J Mol Biol       Date:  2008-09-04       Impact factor: 5.469

5.  Ku86 represses lethal telomere deletion events in human somatic cells.

Authors:  Yongbao Wang; Goutam Ghosh; Eric A Hendrickson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-06       Impact factor: 11.205

6.  The lipid phosphatase activity of PTEN is critical for its tumor supressor function.

Authors:  M P Myers; I Pass; I H Batty; J Van der Kaay; J P Stolarov; B A Hemmings; M H Wigler; C P Downes; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

7.  PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy.

Authors:  Michael Fraser; Helen Zhao; Kaisa R Luoto; Cecilia Lundin; Carla Coackley; Norman Chan; Anthony M Joshua; Tarek A Bismar; Andrew Evans; Thomas Helleday; Robert G Bristow
Journal:  Clin Cancer Res       Date:  2011-11-23       Impact factor: 12.531

8.  Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphatase.

Authors:  Todd R Mereniuk; Mohamed A M El Gendy; Ana M Mendes-Pereira; Christopher J Lord; Sunita Ghosh; Edan Foley; Alan Ashworth; Michael Weinfeld
Journal:  Mol Cancer Ther       Date:  2013-07-24       Impact factor: 6.261

9.  Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond.

Authors:  David Davidson; Lilian Amrein; Lawrence Panasci; Raquel Aloyz
Journal:  Front Pharmacol       Date:  2013-01-31       Impact factor: 5.810

10.  Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas.

Authors:  Michael Krauthammer; Yong Kong; Antonella Bacchiocchi; Perry Evans; Natapol Pornputtapong; Cen Wu; Jamie P. McCusker; Shuangge Ma; Elaine Cheng; Robert Straub; Merdan Serin; Marcus Bosenberg; Stephan Ariyan; Deepak Narayan; Mario Sznol; Harriet M Kluger; Shrikant Mane; Joseph Schlessinger; Richard P Lifton; Ruth Halaban
Journal:  Nat Genet       Date:  2015-07-27       Impact factor: 41.307

View more
  9 in total

1.  Nonhomologous end joining key factor XLF enhances both 5-florouracil and oxaliplatin resistance in colorectal cancer.

Authors:  Zhuo Liu; Miao Yu; Bingyuan Fei; Jing Sun; Dongxin Wang
Journal:  Onco Targets Ther       Date:  2019-03-20       Impact factor: 4.147

2.  Synthetic lethality of a cell-penetrating anti-RAD51 antibody in PTEN-deficient melanoma and glioma cells.

Authors:  Audrey Turchick; Yanfeng Liu; Weixi Zhao; Inessa Cohen; Peter M Glazer
Journal:  Oncotarget       Date:  2019-02-12

3.  USP14 is a deubiquitinase for Ku70 and critical determinant of non-homologous end joining repair in autophagy and PTEN-deficient cells.

Authors:  Arishya Sharma; Turkeya Alswillah; Isha Kapoor; Pal Debjani; Belinda Willard; Matthew K Summers; Zihua Gong; Alexandru Almasan
Journal:  Nucleic Acids Res       Date:  2020-01-24       Impact factor: 16.971

4.  USP14 Regulates DNA Damage Response and Is a Target for Radiosensitization in Non-Small Cell Lung Cancer.

Authors:  Arishya Sharma; Alexandru Almasan
Journal:  Int J Mol Sci       Date:  2020-09-02       Impact factor: 5.923

5.  Therapeutic applications of CRISPR/Cas9 in breast cancer and delivery potential of gold nanomaterials.

Authors:  Jananee Padayachee; Moganavelli Singh
Journal:  Nanobiomedicine (Rij)       Date:  2020-12-24

6.  DNA Damage Response Genes in Osteosarcoma.

Authors:  Ying Tang; Yan-Xia Liu; Xiuning Huang; Peng Li
Journal:  J Oncol       Date:  2021-11-02       Impact factor: 4.375

Review 7.  Acetylation and Deacetylation of DNA Repair Proteins in Cancers.

Authors:  Shiqin Li; Bingbing Shi; Xinli Liu; Han-Xiang An
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

Review 8.  Targeting Genome Stability in Melanoma-A New Approach to an Old Field.

Authors:  Marta Osrodek; Michal Wozniak
Journal:  Int J Mol Sci       Date:  2021-03-28       Impact factor: 5.923

Review 9.  Targeted Cancer Therapy Based on Acetylation and Deacetylation of Key Proteins Involved in Double-Strand Break Repair.

Authors:  Xiwen Wang; Jungang Zhao
Journal:  Cancer Manag Res       Date:  2022-01-22       Impact factor: 3.989

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.